What can be learned from preclinical experiments? And what cannot be learned? What do preclinical researchers need to know about clinical applications? What do clinicians need to learn from preclinical researchers? We will try to answer this! Don’t miss out on this opportunity to deepen your understanding of theranostics and bridge the gap between preclinical imaging and clinical applications. Register now!
Webinar Overview
The theranostic approach combines targeted therapy and diagnostic imaging. It represents a precision medicine approach relying on a specific targeted diagnostic test that helps to select patients for a specific targeted therapy. Molecular imaging in nuclear medicine combines imaging modalities like PET and SPECT with computed tomography (CT) or magnet resonance tomography to derive detailed information on disease. In the clinic, molecular imaging is mainly used for diagnosis, staging, monitoring response to therapy, and selecting patients. Diagnostic imaging can identify those patients who are positive or negative for a target out of a larger population. Subsequently, the patients who are positive can continue with targeted therapy, and patients who are negative can receive conventional therapy. Using preclinical imaging we can learn about targets, (the choice of) ligand, (potentially) which radioisotope to use best, and about tumor biology, which is important for effective theranostics.
Tuesday, 18 June 2024, 16:00 CET | 10:00 EST
What to expect
In this webinar, we’ll try to answer the following questions regarding theranostics and the journey from mice to men: What can and can‘t we learn from preclinical imaging in theranostics? What can be learned from preclinical experiments? And what cannot be learned? What do preclinical researchers need to know about clinical applications? What do clinicians need to learn from preclinical researchers? We will be talking about what makes a good radioligand, what makes a good theranostic target, and what are the opportunities and challenges in facilitating the go/no go decisions. Is the theranostic agent worth a clinical translation?
Who should attend?
This webinar is relevant to those interested in learning more about preclinical imaging and the bridge that can be formed between preclinical imaging and clinical applications. In addition, this webinar will be of interest to multiple profiles in the biomedical research community, especially those applying medical imaging techniques in their work. Clinicians, researchers, PhD students, postdocs, and laboratory technicians will find this webinar relevant.
Speakers
Prof. Dr. Katharina Lückerath
Professor Preclinical Theranostics UK Essen
Prof. Dr. Ken Hermann
Medical Director of the Clinic for Nuclear Medicine UK Essen
